Total submissions: 11
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000844717 | SCV000059734 | pathogenic | Rare genetic deafness | 2012-03-20 | criteria provided, single submitter | clinical testing | The c.2283-1G>T variant in MYO7A has been reported in 8 probands with Usher synd rome (Roux 2011, Bonnet 2011, Jaijo 2011, Roux 2006). 6/8 of these probands were homozygous and 2/8 compound heterozygous. The variant segregated with the disea se in one family and it was absent from 200 control chromosomes (Jaijo 2011). Th e variant alters the invariant region of the 3' splice sequence which leads to s kipping of exon 20, as shown by the analysis of the RNA (Jaijo 2011). In summar y, this variant meets our criteria to be classified as pathogenic for autosomal recessive Usher syndrome. |
Counsyl | RCV000666504 | SCV000790809 | pathogenic | Autosomal recessive nonsyndromic hearing loss 2; Usher syndrome type 1 | 2018-05-30 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV001329739 | SCV001521259 | pathogenic | Autosomal dominant nonsyndromic hearing loss 11 | 2019-09-13 | criteria provided, single submitter | clinical testing | This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868]. This variant has been previously reported as pathogenic [PMID: 16679490, 25798947, 20497194, 25404053, ClinVar ID: 43178] |
Labcorp Genetics |
RCV001383209 | SCV001582289 | pathogenic | not provided | 2024-12-19 | criteria provided, single submitter | clinical testing | This sequence change affects an acceptor splice site in intron 19 of the MYO7A gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in MYO7A are known to be pathogenic (PMID: 8900236, 25404053). This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individuals with Usher syndrome (PMID: 16679490, 20497194, 25404053, 25798947, 31479088). ClinVar contains an entry for this variant (Variation ID: 43178). Studies have shown that disruption of this splice site alters mRNA splicing and is expected to lead to the loss of protein expression (PMID: 20497194). For these reasons, this variant has been classified as Pathogenic. |
Gene |
RCV001383209 | SCV001811922 | pathogenic | not provided | 2023-09-26 | criteria provided, single submitter | clinical testing | Canonical splice site variant in a gene for which loss-of-function is a known mechanism of disease; Not observed in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 20497194, 25798947, 27440999, 31589614, 21569298, 16679490, 21436283, 20301442, 23647439, 24498627, 25560255, 31479088, 33576163, 25404053, 17361009, 35551639, 34948090, 27583663, 34194829) |
3billion, |
RCV000036082 | SCV002059054 | pathogenic | Usher syndrome type 1 | 2022-01-03 | criteria provided, single submitter | clinical testing | Canonical splice site: predicted to alter splicing and result in a loss or disruption of normal protein function through protein truncation. Multiple pathogenic variants are reported in the predicted truncated region (PVS1_VS).The variant has been reported at least twice as pathogenic/likely pathogenic with clinical assertions and evidence for the classification (ClinVar ID: VCV000043178, 3billion dataset). It is not observed in the gnomAD v2.1.1 dataset (PM2_M). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. |
Institute of Human Genetics, |
RCV004814939 | SCV005072173 | pathogenic | Retinal dystrophy | 2021-01-01 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000036082 | SCV000268742 | not provided | Usher syndrome type 1 | no assertion provided | literature only | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV001383209 | SCV001957663 | pathogenic | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV001383209 | SCV001969914 | likely pathogenic | not provided | no assertion criteria provided | clinical testing | ||
Natera, |
RCV001831630 | SCV002086607 | pathogenic | Usher syndrome type 1B | 2021-04-02 | no assertion criteria provided | clinical testing |